New cash-paying patients can now access Wegovy/Ozempic for $199 a month. Here's what that means for Novo Nordisk stock.

The “Before” and “After” photos are breaking the internet. Facebook groups, Reddit threads and gobs of other social media ...

Wegovy’s key competitor is Eli Lilly’s GLP-1 drug Mounjaro (tirzepatide), which became India’s top-selling medicine in ...

Danish drugmaker Novo Nordisk has teamed up with Emcure Pharmaceuticals to increase access to its weight-loss drug ...

A USD 95 billion weight loss revolution is reshaping the global healthcare landscape, and India is emerging as one of its ...

Novo Nordisk has reduced the prices of Wegovy by 37%. The obesity pen's lowest dose of 0.25 mg will sell at Rs 10,850 for a ...

Eli Lilly is well on its way to the trillion-dollar club. The stock price is up 30% so far this year; with a total ...

Danish pharma major Novo Nordisk has slashed the price of Wegovy by up to 37%, to take on its key rival Eli Lilly. Here's how ...

Equity markets delivered a mixed response after Pfizer won the bidding war for anti-obesity drugmaker Metsera, as Metsera’s ...

Danish drugmaker Novo Nordisk on Tuesday announced slashing prices of its weight-loss drug Wegovy by up to 37 per cent in a ...

The starting dose of 0.25 mg will now cost Rs 2,712 per week, down from Rs 4,336 earlier, with the new prices effective ...

The announcement comes as the Danish drugmaker struggles to grab significant market share in the Indian market before it ...